J 2022

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

SCLAFANI, Francesco, Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE et. al.

Basic information

Original name

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

Authors

SCLAFANI, Francesco (guarantor), Elisa FONTANA, Lucjan WYRWICZ, Anna Dorothea WAGNER, Juan W VALLE, Elizabeth SMYTH, Mark PEETERS, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Cindy NEUZILLET, Manfred P LUTZ, Thibaud KOESSLER, Irit BEN-AHARON, Dirk ARNOLD, Maria ALSINA and Markus MOEHLER

Edition

CLINICAL COLORECTAL CANCER, DALLAS, CIG MEDIA GROUP, LP, 2022, 1533-0028

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.400

RIV identification code

RIV/00216224:14110/22:00128356

Organization unit

Faculty of Medicine

UT WoS

000898614900008

Keywords in English

Clinical trials; Meeting; Esophago-gastric cancers; Hepato-pancreatico-biliary cancers; Colorectal cancers

Tags

International impact, Reviewed
Změněno: 30/1/2023 12:51, Mgr. Tereza Miškechová

Abstract

V originále

Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.